FreeTrials & Tribulations Early-onset cancer is on the rise. Here is how OSUCCC–James is adapting to the needs of younger patients March 27, 2026Vol.52 No.12By W. Kimryn Rathmell
Trials & Tribulations In the era of immunotherapy, response rate alone fails to predict true patient benefitRegulators must adapt March 27, 2026Vol.52 No.12By Richard M. Goldberg
Colorectal cancer is now the leading cause of cancer death in patients under 50Why aren’t 45-year-olds getting their recommended CRC screenings? March 27, 2026Vol.52 No.12By Sara Willa Ernst
Sponsored Early-onset colorectal cancer demands a new research playbook March 20, 2026Vol.52 No.11By Marwan Fakih
Clinical Roundup Rectal cancer incidence rising after decades of decline as colorectal cancer shifts toward younger generations, ACS report finds March 06, 2026Vol.52 No.09
Drugs & Targets FDA approves Braftovi combination regimen in first-line metastatic colorectal cancer February 27, 2026Vol.52 No.08
Clinical Roundup Rybrevant leads to anti-tumor activity and durable responses in CRC, phase I/II follow-up results show January 16, 2026Vol.52 No.02
Clinical Roundup Fred Hutch researchers launch free online tool to assess CRC risk January 09, 2026Vol.52 No.1
Guest Editorial Mail-out colorectal cancer screening programs extend, rather than replace, clinical care December 05, 2025Vol.51 No.44By Paul J. Limburg
Clinical Roundup Xilio Therapeutics announces Phase II data for Vilastobart in MSS mCRC November 14, 2025Vol.51 No.42
